



Republic of Serbia
**COMMISSION FOR PROTECTION
OF COMPETITION**

25/IV Savska St., Belgrade
Number: 6/0-02-785/2018-4
Date: December 7, 2018

Published text contains protected data.
Protected data are presented with symbol [...] or in the range that the Commission finds to be an appropriate manner of protection.

Pursuant to Article 37(2) and Article 65(5) of the Law on Protection of Competition (Official Gazette of the RS 51/09 and 95/13), and Article 2(1/6) of the Tariff on the level of compensations for activities within the competence of the Commission for Protection of Competition (Official Gazette of the RS 49/11), deciding under the notification of concentration entered under number 6/0-02-785/2018-1 of November 7, 2018, jointly submitted by companies Fresenius Medical Care AG & KGaA, with registered seat at the address Else-Kröner-Straße 1, 61352 Bad Homburg, Germany, and KR² GmbH, with registered seat at the address Wilhelmshofallee 79-81, 47800, Krefeld, Germany, via procuration holder, attorney at law Danijel Stevanović from the Law Office of Moravčević Vojnović & Partneri, 15 Dobračina St., Belgrade, on December 7, 2018, the President of the Commission for Protection of Competition enacts the following

DECISION

I Concentration of undertakings in summary procedure **IS APPROVED** created by the change of a form of control and acquisition of joint control on the part of companies Fresenius Medical Care Beteiligungs-gesellschaft mbh, company number HRB 3938, with registered seat at the address Else-Kröner-Straße 1, 61352 Bad Homburg, Germany, a wholly owned subsidiary of company Fresenius Medical Care AG & KGaA, company number HRB 4019, with registered seat at the address Else-Kröner-Straße 1, 61352 Bad Homburg, Germany, and KR² GmbH, company number HRB 5472, with registered seat at the address Wilhelmshofallee 79-81, 47800, Krefeld, Germany, over company D.Med Consulting GmbH, company number HRB 154097, with registered seat at the address Bernhard-Norcht-Straße 99, 20359 Hamburg, Germany, created by purchasing 51% of issued shares of company D.Med Consulting AG from the previous shareholder, company KR² GmbH, that keeps the remaining 49% of shares, thus establishing a joint control over the Target company.

II IT IS ESTABLISHED that the Party, company Fresenius Medical Care AG & KGaA, has executed payment in the amount of EUR 25,000.00 (in words: twenty-five thousand euro) on November 16, 2018, to the account of the Commission for Protection of Competition, which represents a stipulated amount of the fee as compensation for issuing decision on approval of concentration in summary procedure.